RET mutant, unresectable, locally advanced or metastatic medullary thyroid cancer and no history of treatment with kinase inhibitors
Selpercatinib (n=193) vs. SOC (Cabozantinib; Vandetanib)
Efficacy
mPFS: NR vs. 16.8 mos, HR: 0.28, p<0.001
12 mos PFS: 86.8% vs. 65.7%
Median treatment failure free survival: NR vs. 13.9 mos, HR:0.25, p<0.001
ORR: 69.4% vs. 39.8%
CR: 11.9% vs. 4.1 %
Safety
Grade3: Hypertension (18.7% vs. 17.5%), ALT increased (10.4% vs. 2.1%), diarrhea (3.1% vs. 8.2%), mucosal inflammation (0.5% ve 13.4%), palmar–plantar erythrodysesthesia syndrome (0 vs. 9.3%)
